Literature DB >> 25248812

Cost effectiveness of percutaneous closure versus medical therapy for cryptogenic stroke in patients with a patent foramen ovale.

Christopher A Pickett1, Todd C Villines2, Michael A Ferguson2, Edward A Hulten2.   

Abstract

In patients with patent foramen ovales (PFOs) and cryptogenic stroke, observational studies have demonstrated reductions in recurrent neurologic events with transcatheter PFO closure compared with medical therapy. Randomized controlled trials and meta-analyses have shown a trend toward benefit with device closure. The cost-effectiveness of PFO closure has not been described. Therefore, a detailed cost analysis was performed using pooled weighted outcome and complication rates from published randomized controlled trials, Medicare cost tables, and wholesale medication prices. Incremental cost per life-year gained and per quality-adjusted life-year (QALY) gained by PFO closure was calculated. The commonly accepted cost-effectiveness threshold of <$50,000/quality-adjusted life-year gained was used. At 2.6 years (the mean duration of randomized controlled trial follow-up), PFO closure was more costly ($16,213, 95% confidence interval [CI] $15,753 to $16,749) per patient, with a cost of $103,607 (95% CI $5,826 to $2,544,750) per life-year gained. The expenditure to prevent 1 combined end point (transient ischemic attack, stroke, and death) at 2.6 years was $1.09 million (95% CI $1.04 million to $1.20 million). Modeling the costs of medical treatment prospectively, PFO closure reached cost-effectiveness (<$50,000/quality-adjusted life-year gained) at 2.6 years (95% CI 1.5 to 44.2). At 30.2 years (95% CI 28.2 to 36.2), the per patient mean cost of medical therapy exceeded that of PFO closure. In conclusion, PFO closure is associated with higher expenditures related to procedural costs; however, this increase may be offset over time by reduced event rates and costs of long-term medical treatment in patients who undergo transcatheter PFO closure. In younger patients typical of cryptogenic stroke, PFO closure may be cost effective in the long term. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248812     DOI: 10.1016/j.amjcard.2014.08.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Role of occlusive devices to prevent thromboembolism among persons with a patent foramen ovale and prior stroke.

Authors:  Christopher Roth; Oluseun Alli
Journal:  Curr Treat Options Neurol       Date:  2015-03       Impact factor: 3.598

Review 2.  [Patent foramen ovale with a license to kill].

Authors:  B Meier
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-03-11       Impact factor: 0.840

3.  Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke.

Authors:  Yoko Shijoh; Shota Saito; Zhehao Dai; Sachiko Ohde
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

4.  Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention.

Authors:  Michelle H Leppert; Sharon N Poisson; John D Carroll; David E Thaler; Chong H Kim; Karen D Orjuela; P Michael Ho; James F Burke; Jonathan D Campbell
Journal:  Stroke       Date:  2018-05-02       Impact factor: 7.914

5.  Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla® Flex II Occluder.

Authors:  Jonas Neuser; Muharrem Akin; Udo Bavendiek; Tibor Kempf; Johann Bauersachs; Julian D Widder
Journal:  BMC Cardiovasc Disord       Date:  2016-11-10       Impact factor: 2.298

Review 6.  Patent foramen ovale and atrial fibrillation as causes of cryptogenic stroke: is treatment with surgery superior to device closure and anticoagulation? A review of the literature.

Authors:  Thomas Kjeld; Tem S Jørgensen; Gitte Fornitz; Jan Roland; Henrik C Arendrup
Journal:  Acta Radiol Open       Date:  2018-08-23

Review 7.  Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Steven R Messé; Gary Gronseth; David M Kent; Jorge R Kizer; Shunichi Homma; Lee Rosterman; Scott E Kasner
Journal:  Neurology       Date:  2016-07-27       Impact factor: 9.910

8.  Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline.

Authors:  Ton Kuijpers; Frederick A Spencer; Reed A C Siemieniuk; Per O Vandvik; Catherine M Otto; Lyubov Lytvyn; Hassan Mir; Albert Y Jin; Veena Manja; Ganesan Karthikeyan; Elke Hoendermis; Janet Martin; Sebastian Carballo; Martin O'Donnell; Trond Vartdal; Christine Baxter; Bray Patrick-Lake; Joanie Scott; Thomas Agoritsas; Gordon Guyatt
Journal:  BMJ       Date:  2018-07-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.